REPLIGEN CORP (RGEN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RGEN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RGEN | Former Vice President, Strategy and Innovation; Director | 66 | ["Public Company Board/CEO", "Risk Oversight", "Strategic Planning and M&A", "Life Sciences Technology & Innovation", "Commercial Sales & Marketing", "Over 30 years of experience leading the development and execution of growth strategies for global life sciences companies", "Vice President, Strategy and Innovation for Thermo Fisher Clinical Services from 2016 to 2020", "Senior Director, Corporate Development & Strategy at Thermo Fisher from 2013 to 2016", "Senior Director, Portable Analytical Instrumentation for Thermo Fisher from 2012 to 2013", "Held senior leadership roles at Philips Healthcare from 1989 to 2000", "Vice President, Business and Clinical Development with Microchips Biomedical from 2006 to 2011", "Independent board director at Alimera Sciences from 2023 to 2024", "Independent director of Jellagen", "Experience with the U.S. subsidiary of BioPorto A/S from 2021 to 2024", "B.A. from the College of Holy Cross", "M.B.A. from Harvard Business School"] | ["Compensation"] | 2026 |
Biography sourced from the proxy statement filing.
Member of the Compensation Committee and Nominating and Corporate Governance Committee. Currently serves as Chairperson of the Compensation Committee. The Board has determined that Ms. Pax is independent within the meaning of the SEC and Nasdaq's director independence standards.